Thymosin Alpha 1: Mechanism of Action

1. Parent Molecule — Prothymosin Alpha

Tα1 e o(a) N-terminal fragment (residues 1–28) do(a) larger precursor protein prothymosin alpha (ProTα), an acidic nuclear protein of 109–111 aminoacidos envolveu in chromatin remodeling and proliferacao celular. ProTα is cleaved pelo(a) lysosomal enzyme legumain (δ-secretase) to release the bioactive Tα1 peptide. [3]

Structural Conformation: In aqueous solution, Tα1 is intrinsically unstructured (disordered). Upon interaction with negatively charged membranes (especialmente those exposing phosphatidylserine) or organic solvents, it adopts a structured conformation with an α-helix from residues 14–26 and two double β-turns no(a) N-terminal residues. [8]

2. Alvo Receptor Primarios

Tα1 functions como um(a) pleiotropic modulator by interacting with pattern recognition receptors (PRRs) and specific membrane components:

• TLR9 and TLR2 Agonist: Signals through TLR9 in plasmacytoid dendritic cells (pDCs) and TLR2 in myeloid dendritic cells (mDCs). [4]
• Membrane Interaction: N-terminal inserts into hydrophobic regions of cell membranes, particularmente those exposing phosphatidylserine (PS) (found on apoptotic cells), triggering signal transduction.
• Hyaluronic Acid (HA) Interaction: C-terminal “LKEKK” motif interacts electrostatically with HA, potentially interfering with CD44/RHAMM binding and suppressing tumor progression.

3. Sinalizacao a Jusante Cascades

A. MyD88 → TRAF6 → IKK → NF-κB (Immune Activation):

TLR9/TLR2 estimulacao recruits the adaptor protein MyD88, activating TRAF6 → IKK complex → NF-κB transcricao factor, promoting cytokine expressao genica (IL-2, IFN-γ, IL-12). Often envolve atypical PKC. [4] [10]

B. p38 MAPK / JNK (DC Maturation):

Tα1 induz fosforilacao of p38 MAPK and JNK (c-Jun N-terminal kinase). The p38 MAPK pathway is critico(a) para dendritic cell maturacao and production of Th1-priming cytokines. [11]

C. cAMP / PKC (Anti-Apoptosis in Thymocytes):

In thymocytes, Tα1 antagonizes steroid-induziu apoptose by stimulating cAMP production and activating PKC-dependent pathways.

D. IDO1 Pathway → Immune Tolerance:

Through TLR9 and Type I interferon receptor signaling, Tα1 induz IDO1 in dendritic cells, activating tryptophan catabolism (kynurenines), que promove generation of regulatory T cells (Tregs) — inducing immune tolerance and dampening excessive inflamacao/cytokine storms. [12]

The product supplied here is for uso em pesquisa apenas independentemente de regulatory status of related formulations.

4. Cellular and Tissue-Level Effects

Dendritic Cells:

• Promotes functional maturacao, increasing expression of HLA-DR, CD86, and CD40
• Stimulates IL-12 production → drives Th1 phenotype (antiviral/antitumor) [4]
• Can also promote tolerance via IDO1 pathway [12]

T-Cells:

• Promotes diferenciacao of celulas-tronco into thymocytes
• Increases ativou CD4+ and CD8+ T cell numbers
• Antagonizes glucocorticoid-induziu apoptose in immature thymocytes

Macrophages:

• Activates complement receptor (CR)-mediated phagocytosis (via actin/vinculin recruitment), distinto(a) de Fc receptor mechanisms [13]
• Dose-dependent response at 50–100 ng/mL

Tumor Cells:

• Upregula MHC Class I expression, making tumors mais visible to cytotoxic T cells
• Can directly inhibit proliferacao celular in certain cancer lines

NK Cells:

• Enhances NK cell activity and function [5]

5. Selectivity and Cross-Reactivity

Tα1 acts como um(a) “regulator of regulators” — modulating the sensitivity of TLRs to outro(a) stimuli (e.g., viral antigens) rather do que solely acting como um(a) direto(a) agonist. It is highly conserved across mammalian species (human, bovine, porcine, ovine). [5]

Distinct from Thymosin Beta-4 (TB-500): While Tα1 focuses on adaptive/innate immune modulacao (TLR/T-cell maturacao), TB-500 is primariamente an actin-sequestering protein envolveu in cell motility, cicatrizacao de feridas, and reparo tecidual.

6. Pharmacokinetics

Parameter	Value
Route	Subcutaneous (standard)
Peak Serum Levels	1–2 hours post-SC injection
Half-Life (T½)	~2 hours
Urinary Excretion	31–60% of administered dose
Dose-Response	Proportional Cmax/AUC for 0.8–6.4 mg single / 1.6–16 mg multiplos(as)
Accumulation	No evidence of accumulation with repeated dosing
Albumin Binding	C-terminal residues 11–20 bind HSA (carrier)